FDA Grants Accelerated Approval of CTI BioPharma’s VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopeniawmosley2022-04-27T15:10:24+00:00March 9th, 2022|
FDA Approves Bristol Myers Squibb’s Opdivo® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancerwmosley2022-04-27T15:11:07+00:00March 8th, 2022|
FDA Approves Janssen Biotech’s CARVYKTI™ (ciltacabtagene autoleucel) a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myelomawmosley2022-04-27T15:11:53+00:00March 1st, 2022|
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia[email protected]2022-01-25T15:14:05+00:00January 25th, 2022|
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery[email protected]2022-01-25T15:13:18+00:00January 25th, 2022|
FDA Approves Amgen’s KYPROLIS (carfilzomib) Combination Regimen w/ DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) & dexamethasone For Patients w/ Multiple Myeloma At First Or Subsequent Relapse[email protected]2022-01-25T15:12:15+00:00January 25th, 2022|